

Beata Franczyk

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9125472/beata-franczyk-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48
papers

654
citations

14
h-index

23
g-index

59
ext. papers

1,016
ext. citations

4.6
avg, IF

4.58
L-index

#	Paper	IF	Citations
48	Arterial Hypertension-Oxidative Stress and Inflammation.. <i>Antioxidants</i> , 2022 , 11,	7.1	7
47	Emerging Anti-Atherosclerotic Therapies. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
46	The Impact of CKD on Uremic Toxins and Gut Microbiota. <i>Toxins</i> , 2021 , 13,	4.9	27
45	Diabetes and Cardiovascular Risk in Renal Transplant Patients. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
44	Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury. <i>Current Medicinal Chemistry</i> , 2021 , 28, 1234-1250	4.3	7
43	The Correlation between Lipid Metabolism Disorders and Prostate Cancer. <i>Current Medicinal Chemistry</i> , 2021 , 28, 2048-2061	4.3	6
42	miRNA biomarkers in renal disease. <i>International Urology and Nephrology</i> , 2021 , 1	2.3	3
41	Metabolomic Profile in Venous Thromboembolism (VTE). <i>Metabolites</i> , 2021 , 11,	5.6	2
40	Are Nutraceuticals Beneficial in Chronic Kidney Disease?. <i>Pharmaceutics</i> , 2021 , 13,	6.4	3
39	Acute Kidney Injury in COVID-19. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
38	Is a High HDL-Cholesterol Level Always Beneficial?. <i>Biomedicines</i> , 2021 , 9,	4.8	1
37	Molecular Interactions of Arterial Hypertension in Its Target Organs. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
36	Oxidative Stress-Related Susceptibility to Aneurysm in Marfan's Syndrome. <i>Biomedicines</i> , 2021 , 9,	4.8	2
35	Mineralocorticoid Receptor Antagonists-Use in Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
34	Pathomechanisms of Immunological Disturbances in β -Thalassemia. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
33	Oxidative Stress in ESRD Patients on Dialysis and the Risk of Cardiovascular Diseases. <i>Antioxidants</i> , 2020 , 9,	7.1	8
32	Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures. <i>International Urology and Nephrology</i> , 2020 , 52, 2135-2143	2.3	14

31	Pharmacogenomics of Hypertension Treatment. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	10
30	The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	25
29	The Influence of Inflammation on Anemia in CKD Patients. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	19
28	Diabetes-induced Alterations in HDL Subfractions Distribution. <i>Current Pharmaceutical Design</i> , 2020 , 26, 3341-3348	3.3	2
27	The Role of Metabolic Factors in Renal Cancers. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
26	Cholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome. <i>Current Vascular Pharmacology</i> , 2019 , 17, 365-375	3.3	8
25	Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients. <i>Nutrients</i> , 2019 , 11,	6.7	8
24	Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients. <i>Nutrients</i> , 2018 , 10,	6.7	19
23	Biomarkers of Cardiovascular Risk in Haemodialysis Patients. <i>Current Pharmaceutical Design</i> , 2018 , 23, 6086-6095	3.3	2
22	Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1857-1865	4	12
21	The occurrence of atrial fibrillation in dialysis patients and its association with left atrium volume before and after dialysis. <i>International Urology and Nephrology</i> , 2017 , 49, 1071-1077	2.3	5
20	Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?. <i>International Urology and Nephrology</i> , 2017 , 49, 155-164	2.3	12
19	Hypertension - Current Natural Strategies to Lower Blood Pressure. <i>Current Pharmaceutical Design</i> , 2017 , 23, 2453-2461	3.3	6
18	Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	112
17	Vegetarian Diet in Chronic Kidney Disease-A Friend or Foe. <i>Nutrients</i> , 2017 , 9,	6.7	42
16	The Effect of Diet on the Survival of Patients with Chronic Kidney Disease. <i>Nutrients</i> , 2017 , 9,	6.7	43
15	Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	1
14	The Use of Plant Sterols and Stanols as Lipid-Lowering Agents in Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2017 , 23, 2488-2495	3.3	18

13	Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?. <i>Current Pharmaceutical Design</i> , 2017 , 23, 3024-3033	3.3	4
12	Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients. <i>Current Vascular Pharmacology</i> , 2017 , 15, 123-134	3.3	3
11	Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , 2016 , 14, 360-7	3.3	10
10	The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , 2016 , 14, 260-5	3.3	8
9	Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2016 , 2016, 9879615	6.7	2
8	Molecular mechanisms of statin intolerance. <i>Archives of Medical Science</i> , 2016 , 12, 645-58	2.9	40
7	Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. <i>Lipids in Health and Disease</i> , 2016 , 15, 22	4.4	19
6	Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2049-56	4	11
5	Sudden cardiac death in CKD patients. <i>International Urology and Nephrology</i> , 2015 , 47, 971-82	2.3	18
4	Heart function disturbances in chronic kidney disease - echocardiographic indices. <i>Archives of Medical Science</i> , 2014 , 10, 1109-16	2.9	26
3	Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. <i>Archives of Medical Science</i> , 2013 , 9, 1019-27	2.9	20
2	Acute coronary syndromes in patients with chronic kidney disease. <i>Current Vascular Pharmacology</i> , 2013 , 11, 758-67	3.3	14
1	Prevention of sudden cardiac death in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2012 , 13, 162	2.7	23